[
  {
    "doc_id": "PMID_41593683",
    "summary": "Evidence for the net benefit of aspirin for primary prevention of cardiovascular disease (CVD) is finely balanced, leading to variation in guideline recommendations internationally. External validity of randomised clinical trial (RCT) evidence may therefore be of particular importance. Rewrite the following clinical statement using only the evidence below. Do not add new information. [95%-CI 1.5-2.5] to 10.5 [95\u201312.4] [95\u201012.5]).Evidence:Evidence for the net benefit of aspirin for primary prevention of cardiovascular disease (CVD) is finely balanced, leading to variation in guideline recommendations internationally. External validity of randomised clinical trial (RCT) evidence may therefore be of particular importance. (95%CI 0.24-0.36] to 11.42 [ 95%CI 9.91-13.17 Rewrite the following clinical statement using only the evidence below. Do not add new information. [95%-CI 1.5-2.5] to 10.5 [95-12.4] to 12.4 [95\u201012.5]).Evidence:Evidence for the net benefit of aspirin for primary prevention of cardiovascular disease (CVD) is finely balanced, leading to variation in guideline recommendations internationally. External validity of randomised clinical trial (RCT) evidence may therefore be of particular importance. (95%CI 0.24-0.36] to 11.42 [ 95%CI 9.91"
  },
  {
    "doc_id": "PMID_41543478",
    "summary": "Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as effective weight loss agents, with growing evidence suggesting potential benefits in MASH. Secondary outcomes included \u22651-point improvements in the nonalcoholic fatty liver disease activity score, changes in liver histologic features, and the incidence of serious adverse events. A total of 6 randomized controlled trials with 1555 patients (1082 GLP- 1RA and 473 placebo) with MASH were included. Rewrite the following clinical statement using only the evidence below. Do not add new information.References:Evidence:Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as effective weight loss agents, with growing evidence suggesting potential benefits in MASH. Secondary outcomes included \u22651-point improvements in the nonalcoholic fatty liver disease activity score, changes in liver histologic features, and the incidence of serious adverse events. A total of 6 randomized controlled trials with 1555 patients (1082 GLP- 1RA and 473 placebo) with MASH were included. The"
  },
  {
    "doc_id": "PMID_41629827",
    "summary": "The global burden of chronic kidney disease (CKD) is increasing, driven largely by risk factors such as hypertension and diabetes. Modifiable lifestyle factors, particularly diet, may play a key role in renal health. Rewrite the following clinical statement using only the evidence below. Do not add new information. This statement is not applicable to the current study.Evidence:Evidence:The global burden of chronic kidney disease (CKD) is increasing, driven largely by risk factors such as hypertension and diabetes. Modifiable lifestyle factors, particularly diet, may play a key role in renal health. These findings highlight the potential for dietary interventions that promote overall healthy eating patterns to contribute to the primary prevention of CKD. Not applicable. This findings highlight-the potential to promote dietary strategies that promote total healthy eating habits to promote a primary prevention for CK Rewrite the following clinical statement using only the evidence below. Do not add new information. This statement is not applicable.Evidence:Evidence:The global burden of chronic kidney disease (CKD) is increasing, driven largely by risk factors such as hypertension and diabetes. Modifiable lifestyle factors, particularly diet, may play a key role in renal health. These findings highlight the potential for dietary interventions that promote overall healthy eating patterns to contribute to the primary prevention of CKD. Not applicable. This findings highlight-the potential to promote dietary strategies that promote total healthy eating habits to promote a primary prevention for CKD, not applicable Rewrite the following clinical statement using only the evidence below. Do not add new information. This statement does not include new evidence.Evidence:Evidence:The global burden of chronic kidney disease (CKD) is increasing, driven largely by risk factors such as hypertension and diabetes. Modifiable lifestyle factors, particularly diet, may play a key role in renal health. These findings highlight the potential for dietary interventions that promote overall healthy eating patterns to contribute to the primary prevention of CKD. Not applicable. This findings highlight-the potential to promote dietary strategies that promote total healthy eating habits to promote a primary prevention for CKD, Rewrite the following clinical statement using only the evidence below. Do not add new information.References [ edit ]Clinical Statement:Evidence:The global burden of chronic kidney disease (CKD) is increasing, driven largely by risk factors such as hypertension and diabetes. Modifiable lifestyle factors, particularly diet, may play a key role in renal health. These findings highlight the potential for dietary interventions that promote overall healthy eating patterns to contribute to the primary prevention of CKD. Not applicable. This findings highlight-the potential to promote dietary strategies that promote total healthy eating habits to promote a primary prevention for CKD, not applicable"
  },
  {
    "doc_id": "PMID_41551204",
    "summary": "We aim to evaluate the effectiveness of the novel real-time continuous glucose monitoring (rtCGM) system \" This prospective, open-label, randomized controlled trial included 172 patients with T2D from the Fatebenefratelli-Sacco Hospital in Milan. Participants were randomized into 2 groups: 86 patients received the After 6 months, the The use of the NCT07089979."
  },
  {
    "doc_id": "PMID_41592063",
    "summary": "This study evaluated the accuracy of phosphatidylethanol (PEth), a direct biomarker of alcohol consumption, in distinguishing individuals with and without heavy drinking days, and sought to establish an optimal cutoff using data from a recent clinical trial in alcohol use disorder (AUD). Rewrite the following clinical statement using only the evidence below. Do not add new information. Please do not add additional information.Evidence:This study evaluated the accuracy of phosphatidylethanol (PEth), a direct biomarker of alcohol consumption, in distinguishing individuals with and without heavy drinking days, and sought to establish an optimal cutoff using data from a recent clinical trial in alcohol use disorder (AUD). Moderate-to-strong correlations were observed, strongest at Week 4 (Rho = 0.65, 95% CI, 0.52-0.75, P <.001) and at Week 5 ( Rewrite the following clinical statement using only the evidence below. Do not add new information. This is a summary of the clinical statement.Evidence:This study evaluated the accuracy of phosphatidylethanol (PEth), a direct biomarker of alcohol consumption, in distinguishing individuals with and without heavy drinking days, and sought to establish an optimal cutoff using data from a recent clinical trial in alcohol use disorder (AUD). Moderate-to-strong correlations were observed, strongest at Week 4 (Rho = 0.65, 95% CI, 0.52-0.75, P <.001) and at Week Moderate to Strong correlations are observed. Rewrite the following clinical statement using only the evidence below. Do not add new information. Please do not add additional information.Evidence:This study evaluated the accuracy of phosphatidylethanol (PEth), a direct biomarker of alcohol consumption, in distinguishing individuals with and without heavy drinking days, and sought to establish an optimal cutoff using data from a recent clinical trial in alcohol use disorder (AUD). Moderate-to-strong correlations were observed, strongest at Week 4 (Rho = 0.65, 95% CI, 0.52-0.75, P <.001) and at Week 5 ("
  },
  {
    "doc_id": "PMID_41540107",
    "summary": "In patients with stable coronary artery disease (CAD), the long-term benefits of revascularization over medical therapy remain unclear. PCI was superior in 29.2% of comparisons, medical therapy in 23.3%, and the two groups were tied in 47.5%, resulting in a win ratio of 1.25 in favor of PCI (95% confidence interval (CI) 1.01-1.56, P = 0.043). In patients with Stable CAD, the Long-term Benefits of Revascularization Over Medical Therapy Remain unclear. Rewrite the following clinical statement using only the evidence below. Do not add new information. This statement does not include any new data.Evidence:Evidence:In patients with stable coronary artery disease (CAD), the long-term benefits of revascularization over medical therapy remain unclear. PCI was superior in 29.2% of comparisons, medical therapy in 23.3%, and the two groups were tied in 47.5%, resulting in a win ratio of 1.25 in favor of PCI (95% confidence interval (CI) 1.01-1.56, P = 0.043). In patients with St PCI and medical therapy are tied in 46.5%. Rewrite the following clinical statement using only the evidence below. Do not add new information. This statement does not include new data.Evidence:In patients with stable coronary artery disease (CAD), the long-term benefits of revascularization over medical therapy remain unclear. PCI was superior in 29.2% of comparisons, medical therapy in 23.3%, and the two groups were tied in 47.5%, resulting in a win ratio of 1.25 in favor of PCI (95% confidence interval (CI) 1.01-1.56, P = 0.043). In patients with Stable CAD,"
  },
  {
    "doc_id": "PMID_41629143",
    "summary": "Rewrite the following clinical statement using only the evidence below. Do not add new information. This statement does not contain any new evidence.Evidence:SGLT2 inhibitorsTheir mechanism combines moderate osmotic natriuresis, selective reduction of extracellular volume, renal protection, and minimal neurohormonal activation. In clinical practice, their combination with diuretics requires careful titration to prevent hypovolemia, hypotension, and renal dysfunction, especially in frail elderly patients. Evidence suggests that SGLT 2i may reduce chronic diuretic requirements, improve renal function, and provide additional cardiovascular protection.Evidence In clinical practice, their combination with diuretics requires careful titration to prevent hypovolemia, hypotension, and renal dysfunction, especially in frail elderly patients. Evidence suggests that SGLT 2i may reduce chronic diuretic requirements, improve renal function, and provide additional cardiovascular protection."
  },
  {
    "doc_id": "PMID_41654775",
    "summary": "This study aimed to evaluate the risk of doxorubicin-induced cardiotoxicity in newly diagnosed breast cancer patients with type 2 diabetes receiving dapagliflozin in addition to metformin, using echocardiographic methods, and to investigate the potential cardioprotective effects of dapazlozin. Rewrite the following clinical statement using only the evidence below. Do not add new information. This is a summary of the clinical statement.Evidence:This study aimed to evaluate the risk of doxorubicin-induced cardiotoxicity in newly diagnosed breast cancer patients with type 2 diabetes receiving dapagliflozin in addition to metformin, using echocardiographic methods, and to investigate the potential cardioprotective effects of dapazlozin. In this prospective observational study, a total of 60 newly diagnosed women with type 1 diabetes were enrolled. Within-group changes from baseline to 3 Within-group changes from baseline to 3 months were analyzed with paired t-tests. Rewrite the following clinical statement using only the evidence below. Do not add new information. This is a summary of the clinical statement.Evidence:This study aimed to evaluate the risk of doxorubicin-induced cardiotoxicity in newly diagnosed breast cancer patients with type 2 diabetes receiving dapagliflozin in addition to metformin, using echocardiographic methods, and to investigate the potential cardioprotective effects of dapazlozin. In this prospective observational study, a total of 60 newly diagnosed women with type 1 diabetes were enrolled. Within-group changes from baseline to 3 Rewrite the following clinical statement using only the evidence below. Do not add new information. This is a summary of the clinical statement.Evidence:Dapagllozin-induced cardiotoxicity in newly diagnosed breast cancer patients with type 2 diabetesAbstractBackground:This study aimed to evaluate the risk of doxorubicin and dapagliflozin and metformin- induced cardiot cytotoxicity (DAP-proBNP) and newly diagnosed metastatic breast cancer patient with type 1 diabetes receiving dapazlozin. The study was conducted using independent, randomized, and multivariable Rewrite the following clinical statement using only the evidence below. Do not add new information. This is a summary of the clinical statement.Evidence:This study aimed to evaluate the risk of doxorubicin-induced cardiotoxicity in newly diagnosed breast cancer patients with type 2 diabetes receiving dapagliflozin in addition to metformin, using echocardiographic methods, and to investigate the potential cardioprotective effects of dapazlozin. In this prospective observational study, a total of 60 newly diagnosed women with type 1 diabetes were enrolled. Within-group changes from baseline to 3"
  },
  {
    "doc_id": "PMID_41609932",
    "summary": "Antidepressant augmentation with bupropion was recently demonstrated to increase fall risk in older adults, though specific subpopulations that may have increased risk have not yet been identified. There were significant main effects of bpropion dosage level (low, medium, or high) (p = 0.04) and number of falls during the six months prior to study entry (p < 0.001). There were major effects of bupropionic dosage level, low, medium ( or high), (p > 0.05) and (p \u2265 0.01) and total number of fall during the 6 months prior (p< 0.02). Rewrite the following clinical statement using only the evidence below. Do not add new information. This is a summary of the clinical statement.Evidence:Evidence:Antidepressant augmentation with bupropion was recently demonstrated to increase fall risk in older adults, though specific subpopulations that may have increased risk have not yet been identified. There were significant main effects of bpropion dosage level (low, medium, or high) (p = 0.04) and number of falls during the six months prior to study entry (p < 0.001). There were major effects of bupropionic dosage level, low,"
  },
  {
    "doc_id": "PMID_41553512",
    "summary": "Heart failure (HF) patients with concomitant coronary artery disease (CAD) and type 2 diabetes mellitus (DM) represent a particularly high-risk population with increased morbidity and mortality. Acute coronary syndrome (ACS) often serves as a critical event that can trigger the initiation of guideline-directed medical therapy (GDMT). Rewrite the following clinical statement using only the evidence below. Do not add new information. This is a summary of the clinical statement.Evidence:Heart failure (HF) patients with concomitant coronary artery disease (CAD) and type 2 diabetes mellitus (DM) represent a particularly high-risk population with increased morbidity and mortality. Acute coronary syndrome (ACS) often serves as a critical event that can trigger the initiation of guideline-directed medical therapy (GDMT). Statin use increased from 22.3% to 82.4%, ACEi/ARB/ARNI from 58.2% to Rewrite the following clinical statement using only the evidence below. Do not add new information. This is a summary of the clinical statement.Evidence:Heart failure (HF) patients with concomitant coronary artery disease (CAD) and type 2 diabetes mellitus (DM) represent a particularly high-risk population with increased morbidity and mortality. Acute coronary syndrome (ACS) often serves as a critical event that can trigger the initiation of guideline-directed medical therapy (GDMT). Statin use increased from 22.3% to 82.4%, ACEi/ARB/ARNI from 58.2% to Rewrite the following clinical statement using only the evidence below. Do not add new information. This is a summary of the clinical statement.Evidence:Heart failure (HF) patients with concomitant coronary artery disease (CAD) and type 2 diabetes mellitus (DM) represent a particularly high-risk population with increased morbidity and mortality. Acute coronary syndrome (ACS) often serves as a critical event that can trigger the initiation of guideline-directed medical therapy (GDMT). Statin use increased from 22.3% to 82.4%, ACEi/ARB/ARNI from 58.2% to Rewrite the following clinical statement using only the evidence below. Do not add new information. This is a summary of the clinical statement.Evidence:Heart failure (HF) patients with concomitant coronary artery disease (CAD) and type 2 diabetes mellitus (DM) represent a particularly high-risk population with increased morbidity and mortality. Acute coronary syndrome (ACS) often serves as a critical event that can trigger the initiation of guideline-directed medical therapy (GDMT). Statin use increased from 22.3% to 82.4%, ACEi/ARB/ARNI from 58.2% to"
  },
  {
    "doc_id": "PMID_41572076",
    "summary": "The behavioural tests were performed after eight weeks of inducing diabetes. Real-time polymerase chain reaction was used to carry out expression analysis. Rewrite the following clinical statement using only the evidence below. Do not add new information.METHODOLOGY:METHODOLOGYEvidence:Evidence:The behavioural tests were performed after eight weeks of inducing diabetes. Real-time polymerase chain reaction was used to carry out expression analysis. These findings highlight potential therapeutic targets for mitigating diabetes-associated neurobehavioral dysfunction. The behavioural tests (Fig. 1) were performed at eight weeks after inducing diabetes, and after 8 weeks of induced diabetes. The clinical statement (Supplementary Fig. 2) does not add any new information to the clinical statement.Methodology:Evidence-Based Clinical Statement: Rewrite the following clinical statement using only the evidence below. Do not add new information.METHODOLOGY:METHODOLOGYEvidence:Evidence:The behavioural tests were performed after eight weeks of inducing diabetes. Real-time polymerase chain reaction was used to carry out expression analysis. These findings highlight potential therapeutic targets for mitigating diabetes-associated neurobehavioral dysfunction. The behavioural tests (Fig. 1) were performed at eight weeks after inducing diabetes, and after 8 weeks of induced diabetes.Methodology:Methodology of the clinical statement (Supplementary Information)Evidence:Psychological evidenceEvidence:Physical evidence:Physical Evidence:PhysicalEvidence: Rewrite the following clinical statement using only the evidence below. Do not add new information.References:Evidence:The behavioural tests were performed after eight weeks of inducing diabetes. Real-time polymerase chain reaction was used to carry out expression analysis. These findings highlight potential therapeutic targets for mitigating diabetes-associated neurobehavioral dysfunction. The behavioural tests (Fig. 1) were performed at eight weeks after inducing diabetes, and after 8 weeks of induced diabetes. The clinical statement (Supplementary Table S1) did not add any new information to the clinical statement.Statement:The clinical statements (Supplementaries S1 and S2) Rewrite the following clinical statement using only the evidence below. Do not add new information.(Source: The authors\u2019 paper)Evidence:Evidence:The behavioural tests were performed after eight weeks of inducing diabetes. Real-time polymerase chain reaction was used to carry out expression analysis. These findings highlight potential therapeutic targets for mitigating diabetes-associated neurobehavioral dysfunction. The behavioural tests (Fig. 1) were performed at eight weeks after inducing diabetes, and after 8 weeks of induced diabetes.The clinical statement is as follows:Statement:The evidence was presented after two weeks of induce diabetes. (Source: the authors\ufffd"
  },
  {
    "doc_id": "PMID_41623057",
    "summary": "The pullback pressure gradient (PPG) is a novel physiological metric that quantifies coronary artery disease patterns as focal or diffuse on a scale from 0 to 1. The mean age was 67.6\u00b110.2 years, 24% were female, and 29% had diabetes. Rewrite the following clinical statement using only the evidence below. Do not add new information.References:Evidence:The pullback pressure gradient (PPG) is a novel physiological metric that quantifies coronary artery disease patterns as focal or diffuse on a scale from 0 to 1. The mean age was 67.6\u00b110.2 years, 24% were female, and 29% had diabetes. The median age was 66.5\u00b19.5 years, 25% were male, and 24% had female. At 1 year, patients with focal coronary artery diseases reported less angina than those with diffuse coronary artery Disease ( At 1 year, patients with focal coronary artery diseases reported less angina than those with diffuse coronary artery Disease (Seattle Angina Questionnaire angina frequency score, 95.3\u00b1 9.9 versus 92.7\u00b115.0; In patients with flow-limiting coronary artery disorder, the presence of focal disease defined by high PPG was associated with greater symptomatic relief at 1 year compared with diffuse disease (low PPG)."
  },
  {
    "doc_id": "PMID_41574965",
    "summary": "Effective anti-obesity interventions that preserve lean mass are of increasing clinical significance for optimizing metabolic health. Lorcaserin reduced total body weight (time*treatment, p = 0.004). Rewrite the following clinical statement using only the evidence below. Do not add new information. This statement does not support the hypothesis that reducing total body fat mass may improve cardiometabolic health primarily through reductions in central adiposity. The following clinical statements are supported by the following evidence:Evidence: \u00a0 \u00a0Effective anti-obesity interventions that preserve lean mass are of increasing clinical significance for optimizing metabolic health. Lorcaserin reduced total body weight (time*treatment, p = 0.004). Lorcasersin reduced abdominal fat mass (time-treated, p < 0.001). Adjusted delta and endpoint comparisons showed reductions Rewrite the following clinical statement using only the evidence below. Do not add new information. This statement does not support the hypothesis that reducing total body fat mass may improve cardiometabolic health primarily through reductions in central adiposity.Lorcaserin Reduced total body weight (time*treatment, p = 0.004). Lorcasersin reduced total body mass (time-treated, p < 0.001). Adjusted delta and endpoint comparisons showed reductions in total body (p = 0 and 0.031) and abdominal fat (p > 0.002). These results support the notion that reducing overall body weight may improve Rewrite the following clinical statement using only the evidence below. Do not add new information. This statement supports the hypothesis that reducing total body fat mass may improve cardiometabolic health primarily through reductions in central adiposity. The following clinical statements support the hypothesis.Evidence: \u00a0 \u00a0Effective anti-obesity interventions that preserve lean mass are of increasing clinical significance for optimizing metabolic health. Lorcaserin reduced total body weight (time*treatment, p = 0.004). Lorcasersin reduced abdominal fat mass (time-treated, p < 0.001). Adjusted delta and endpoint comparisons showed reductions in total body (p"
  },
  {
    "doc_id": "PMID_41539381",
    "summary": "Seasonal peaks are consistently associated with excess hospitalizations and mortality. Systemic inflammation, plaque destabilization, metabolic imbalance, endothelial dysfunction, and pro-thrombotic activation collectively contribute to acute coronary syndromes, myocarditis, arrhythmias, and acute or worsening heart failure. Despite the availability of effective and inexpensive vaccines, influenza vaccination remains underused in high-risk cardiovascular populations. Randomized trials and meta-analyses consistently support vaccination as a powerful preventive tool, associated with a 25-37% reduction in major adverse cardiovascular events and mortality, with benefits comparable to established cardioprotective therapies."
  },
  {
    "doc_id": "PMID_41625815",
    "summary": "Diabetes mellitus is a leading cause of global mortality with significant health complications. Psychological measures improved, with PSS scores dropping from 17.7 \u00b1 3.2 to 9.80 \u00b1 1.67 in YG and 16.0 \u00b1 2.3 to 9 (53 \u00b1 1. )48 in CYG; smaller reductions occurred in GH and Control. Rewrite the following clinical statement using only the evidence below. Do not add new information. This is a summary of the clinical statement.Evidence:Diabetes mellitus is a leading cause of global mortality with significant health complications. Psychological measures improved, with PSS scores dropping from 17.7 \u00b1 3.2 to 9.80 \u00b1 1.67 in YG and 16.0 \u00b1 2.3 to 9 (53 \u00b1 1.)48 in CYG; smaller reductions occurred in GH and Control. Psychological Measures improved, as PSS scored dropped from 15.5 \u00b1 4.0 to 8.8 \u00b1 0. Rewrite the following clinical statement using only the evidence below. Do not add new information. This is a summary of the clinical statement.Evidence:Diabetes mellitus is a leading cause of global mortality with significant health complications. Psychological measures improved, with PSS scores dropping from 17.7 \u00b1 3.2 to 9.80 \u00b1 1.67 in YG and 16.0 \u00b1 2.3 to 9 (53 \u00b1 1) to 9,53\u2013 1.48 in CYG; smaller reductions occurred in GH and Control. Psychological Measures improved, as PSS scored dropped from 15.5 \u00b1 4.0 Rewrite the following clinical statement using only the evidence below. Do not add new information. This is a summary of the evidence.Evidence:Diabetes mellitus is a leading cause of global mortality with significant health complications. Psychological measures improved, with PSS scores dropping from 17.7 \u00b1 3.2 to 9.80 \u00b1 1.67 in YG and 16.0 \u00b1 2.3 to 9 (53 \u00b1 1) to 9,53\u2013 1.48 in CYG; smaller reductions occurred in GH and Control. Psychological Measures improved, as PSS scored dropped from 15.5 \u00b1 4.0 to"
  },
  {
    "doc_id": "PMID_41557987",
    "summary": "Adherence was measured semiannually for 3 years using a validated three-item scale (0-100, lowest to highest adherence) in a substudy (N = 1,739). Analyses included evaluation of adherence over time and testing treatment group differences in adherence and in the association between adherence and primary (HbA1c \u22657.0%) and secondary (Habato1c >7.5%) glycemic outcomes (both P < 0.0001). Rewrite the following clinical statement using only the evidence below. Do not add new information. This is a summary of the evidence presented in this study.Evidence:Adherence was measured semiannually for 3 years using a validated three-item scale (0-100, lowest to highest adherence) in a substudy (N = 1,739). Analyses included evaluation of adherence over time and testing treatment group differences in adherence and in the association between adherence and primary (HbA1c \u22657.0%) and secondary (Habato1c >7.5%) glycemic outcomes (both P Rewrite the following clinical statement using only the evidence below. Do not add new information. This is a summary of the evidence.Evidence:Adherence was measured semiannually for 3 years using a validated three-item scale (0-100, lowest to highest adherence) in a substudy (N = 1,739). Analyses included evaluation of adherence over time and testing treatment group differences in adherence and in the association between adherence and primary (HbA1c \u22657.0%) and secondary (Habato1c >7.5%) glycemic outcomes (both P < 0.0001"
  },
  {
    "doc_id": "PMID_41533371",
    "summary": "Pancreas divisum is implicated as an obstructive cause for acute pancreatitis. Observational data suggest endoscopic retrograde cholangiopancreatography (ERCP) with minor papillotomy reduces the risk of pancreatitis episodes. The trial was conducted between September 1, 2018, and August 30, 2024, at 21 referral centers in the US and Canada. Last follow-up occurred on February 15, 2025. Rewrite the following clinical statement using only the evidence below. Do not add new information. Refer to the ClinicalTrials.gov Identifier: NCT03609944.Evidence:Pancreas divisum is implicated as an obstructive cause for acute pancreatitis. Observational data suggest endoscopic retrograde cholangiopancreatography (ERCP) with minor papillotomy reduces the risk of pancreatitis episodes. The trial was conducted between September 1, 2018, and August 30, 2024, at 21 referral centers in the US and Canada. Last follow-up occurred on February 15, 2025. Rewrite the following clinical statement using only the evidence below. Do not add new information.Clinical Trials.govEvidence:Pancreas divisum is implicated as an obstructive cause for acute pancreatitis. Observational data suggest endoscopic retrograde cholangiopancreatography (ERCP) with minor papillotomy reduces the risk of pancreatitis episodes. The trial was conducted between September 1, 2018, and August 30, 2024, at 21 referral centers in the US and Canada. Last follow-up occurred on February 15, 2025. ClinicalTrials.gov Identifier: NCT036099 Rewrite the following clinical statement using only the evidence below. Do not add new information. PubMed Abstract | CrossRef Full Text | Google Scholar | Full TextEvidence:Pancreas divisum is implicated as an obstructive cause for acute pancreatitis. Observational data suggest endoscopic retrograde cholangiopancreatography (ERCP) with minor papillotomy reduces the risk of pancreatitis episodes. The trial was conducted between September 1, 2018, and August 30, 2024, at 21 referral centers in the US and Canada. Last follow-up occurred on February 15, 2025. ClinicalTrials.gov"
  },
  {
    "doc_id": "PMID_41550872",
    "summary": "The optimal combination therapy for heart failure with reduced ejection fraction (HFrEF) involving sodium-glucose transporter 2 inhibitors (SGLT2i), angiotensin receptor-neprilysin inhibitors (ARNI), and conventional triple therapy remains uncertain due to the lack of direct comparative evidence. We conducted a Bayesian network meta-analysis of randomized controlled trials (RCTs) comparing six treatment regimens. Rewrite the following clinical statement using only the evidence below. Do not add new information.References:Evidence:The optimal combination therapy for heart failure with reduced ejection fraction (HFrEF) involving sodium-glucose transporter 2 inhibitors (SGLT2i), angiotensin receptor-neprilysin inhibitors (ARNI), and conventional triple therapy remains uncertain due to the lack of direct comparative evidence. We conducted a Bayesian network meta-analysis of randomized controlled trials (RCTs) comparing six treatment regimens. The safety profiles differ significantly, particularly regarding hypotension risk with ARNI and Rewrite the following clinical statement using only the evidence below. Do not add new information. The data were obtained from six randomized controlled controlled trials and from six RCTs comparing six therapy regimens.Evidence:The optimal combination therapy for heart failure with reduced ejection fraction (HFrEF) involving sodium-glucose transporter 2 inhibitors (SGLT2i), angiotensin receptor-neprilysin inhibitors (ARNI), and conventional triple therapy remains uncertain due to the lack of direct comparative evidence. We conducted a Bayesian network meta-analysis of randomized controlled trials (RCTs) comparing Rewrite the following clinical statement using only the evidence below. Do not add new information. The data were obtained from six randomized controlled controlled trials and from six RCTs comparing six therapy regimens.Evidence:The optimal combination therapy for heart failure with reduced ejection fraction (HFrEF) involving sodium-glucose transporter 2 inhibitors (SGLT2i), angiotensin receptor-neprilysin inhibitors (ARNI), and conventional triple therapy remains uncertain due to the lack of direct comparative evidence. We conducted a Bayesian network meta-analysis of randomized controlled trials (RCTs) comparing"
  }
]